Scholarlink

Background <p>Studies have reported conflicting findings regarding whether attention-deficit/hyperactivity disorder (ADHD) and neurostimulant (NS) treatment influence growth. The study aimed to evaluate the impact of ADHD and NS-treatment on adult height (AH), while accounting for individual expected height.</p> Methods <p>Retrospective controlled cohort study using a nationwide healthcare provider database. Children born 1995-2003 were classified into: (1) untreated ADHD, (2) NS-treated ADHD, and (3) controls, followed until AH (girls ≥17 years, boys ≥19 years). Observed height index (OHI) = individual AH ÷ sex-specific mean AH of controls. Expected height index (EHI) = individual’s MPH ÷ sex-specific mean MPH of controls. Normalized height deviance (NHD) = OHI − EHI. ADHD impact = mean NHD(untreated ADHD) − mean NHD(controls). NS-treatment impact = mean NHD(NS-treated) − mean NHD(untreated ADHD). Significance was set at <i>p</i> ≤ 0.05. Effect sizes reported as Cohen’s <i>d</i> and <i>f</i>.</p> Results <p>The cohort included 17,517 children with ADHD (5671 untreated; 11,846 NS-treated) and 47,258 controls. Girls’ ADHD impact was −0.28% (<i>p</i> &lt; 0.001; Cohen’s <i>d</i> = 0.08), and in boys −0.11% (<i>p</i> = 0.12; Cohen’s <i>d</i> = 0.03). Girls’ NS-treatment impact was −0.26% (<i>p</i> = 0.005, Cohen’s <i>d</i> = 0.07), in boys −0.10% (<i>p</i> = 0.25).</p> Conclusions <p>ADHD and NS-treatment were associated with negligible effect sizes in girls and non-significant differences in boys.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>After accounting for individual familial genetic height potential, ADHD and neurostimulant treatment are associated with statistically detectable but clinically negligible differences in adult height.</p> </ItemContent> <ItemContent> <p>Introduces normalized height deviance (NHD), a genetics-adjusted measure that distinguishes true growth effects from delayed maturation.</p> </ItemContent> <ItemContent> <p>Uses a large, nationwide cohort followed to adult height, resolving long-standing inconsistencies in prior growth studies.</p> </ItemContent> <ItemContent> <p>Provides reassurance that ADHD and neurostimulant treatment do not meaningfully impair final adult stature and supports informed clinical decision-making.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of ADHD and neurostimulant treatment on normalized height deviance after accounting for genetic height potential

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Michal Gabbay,
  • Uri Gabbay,
  • Doron Carmi

摘要

Background

Studies have reported conflicting findings regarding whether attention-deficit/hyperactivity disorder (ADHD) and neurostimulant (NS) treatment influence growth. The study aimed to evaluate the impact of ADHD and NS-treatment on adult height (AH), while accounting for individual expected height.

Methods

Retrospective controlled cohort study using a nationwide healthcare provider database. Children born 1995-2003 were classified into: (1) untreated ADHD, (2) NS-treated ADHD, and (3) controls, followed until AH (girls ≥17 years, boys ≥19 years). Observed height index (OHI) = individual AH ÷ sex-specific mean AH of controls. Expected height index (EHI) = individual’s MPH ÷ sex-specific mean MPH of controls. Normalized height deviance (NHD) = OHI − EHI. ADHD impact = mean NHD(untreated ADHD) − mean NHD(controls). NS-treatment impact = mean NHD(NS-treated) − mean NHD(untreated ADHD). Significance was set at p ≤ 0.05. Effect sizes reported as Cohen’s d and f.

Results

The cohort included 17,517 children with ADHD (5671 untreated; 11,846 NS-treated) and 47,258 controls. Girls’ ADHD impact was −0.28% (p < 0.001; Cohen’s d = 0.08), and in boys −0.11% (p = 0.12; Cohen’s d = 0.03). Girls’ NS-treatment impact was −0.26% (p = 0.005, Cohen’s d = 0.07), in boys −0.10% (p = 0.25).

Conclusions

ADHD and NS-treatment were associated with negligible effect sizes in girls and non-significant differences in boys.

Impact

After accounting for individual familial genetic height potential, ADHD and neurostimulant treatment are associated with statistically detectable but clinically negligible differences in adult height.

Introduces normalized height deviance (NHD), a genetics-adjusted measure that distinguishes true growth effects from delayed maturation.

Uses a large, nationwide cohort followed to adult height, resolving long-standing inconsistencies in prior growth studies.

Provides reassurance that ADHD and neurostimulant treatment do not meaningfully impair final adult stature and supports informed clinical decision-making.